The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits.

In a Perspective, Jacqueline Deeen discusses challenges in balancing the individual and population risks and benefits for CYD-TDV (Dengvaxia), the first available dengue vaccine.

Bibliographic Details
Main Author: Jacqueline Deen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-11-01
Series:PLoS Medicine
Online Access:http://europepmc.org/articles/PMC5127493?pdf=render
id doaj-05f0810d27b54567b922d41f8fa9da87
record_format Article
spelling doaj-05f0810d27b54567b922d41f8fa9da872020-11-25T00:43:37ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762016-11-011311e100218210.1371/journal.pmed.1002182The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits.Jacqueline DeenIn a Perspective, Jacqueline Deeen discusses challenges in balancing the individual and population risks and benefits for CYD-TDV (Dengvaxia), the first available dengue vaccine.http://europepmc.org/articles/PMC5127493?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Jacqueline Deen
spellingShingle Jacqueline Deen
The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits.
PLoS Medicine
author_facet Jacqueline Deen
author_sort Jacqueline Deen
title The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits.
title_short The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits.
title_full The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits.
title_fullStr The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits.
title_full_unstemmed The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits.
title_sort dengue vaccine dilemma: balancing the individual and population risks and benefits.
publisher Public Library of Science (PLoS)
series PLoS Medicine
issn 1549-1277
1549-1676
publishDate 2016-11-01
description In a Perspective, Jacqueline Deeen discusses challenges in balancing the individual and population risks and benefits for CYD-TDV (Dengvaxia), the first available dengue vaccine.
url http://europepmc.org/articles/PMC5127493?pdf=render
work_keys_str_mv AT jacquelinedeen thedenguevaccinedilemmabalancingtheindividualandpopulationrisksandbenefits
AT jacquelinedeen denguevaccinedilemmabalancingtheindividualandpopulationrisksandbenefits
_version_ 1725277347217670144